ClinicalTrials.gg
CompletedNCT05565729Updated Nov 18, 2023

A Phase I Study of LY3471851 in Healthy Participants

A Phase 1 interventional study of LY3471851 and Placebo in Healthy, sponsored by Nektar Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Nektar Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The purpose of this study is to compare two different formulations (test \& reference) of LY3471851 in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving the study drug that is LY3471851.

02

Conditions studied

  • Healthy

Keywords

  • Interleukin-2
  • NKTR-358
  • Pharmacokinetics
03

In context

Lead sponsor

Nektar Therapeutics is the lead sponsor of 39 studies on the registry; 2 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 13 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical history and physical examination
  • Have body weight greater than 45 kilograms (kg) and within the range 18.0 to 32.0 kilograms per square meter (kg/m²)
  • Male and female participants must agree to adhere to requirements

Exclusion criteria

Exclusion Criteria:

  • Have an abnormality in the 12-lead (ECG), vital signs, or both
  • Have had symptomatic herpes zoster within 3 months prior to screening
  • Have a known allergy or to levocetirizine
  • Intend to use prescription or nonprescription medication within 14 days or 5 half-lives prior to dosing
  • Have received treatment with biologic agents within 3 months or 5 half-lives prior to dosing
  • Smoke more than 10 cigarettes or other tobacco products per day before study entry
  • Are pregnant or breastfeeding, or intend to become pregnant or breastfeed during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    LY3471851 (Test formulation)

    LY3471851 administered subcutaneously (SC).

    Drug: LY3471851

  • Experimental
    LY3471851 (Test) + Levocetirizine

    LY3471851 administered SC in combination with levocetirizine given orally.

    Drug: LY3471851 · Drug: Levocetirizine

  • Active comparator
    LY3471851 (Reference formulation)

    LY3471851 administered SC.

    Drug: LY3471851

  • Placebo comparator
    Placebo

    Placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC.

    Also known as: NKTR-358

  • DrugPlacebo

    Administered SC.

  • Administered orally.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851

    PK: Cmax of LY3471851

    Time frame: Predose up to 56 days postdose

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY3471851

    PK: AUC of LY3471851

    Time frame: Predose up to 56 days postdose

07

Study locations

1 site
  • Covance Dallas
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Feb 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 4, 2022
StartActual
Oct 5, 2022
Primary completionActual
Feb 23, 2023
CompletionActual
Feb 23, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05565729
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Oct 5, 2022
Primary completion
Feb 23, 2023
Completion
Feb 23, 2023
Last update
Nov 18, 2023

Study contacts

Study Director
study director · Nektar Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezpegaldesleukin

Start the discussion